Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

NattoPharma ASA: NATTO : INITIATION OF STRATEGIC REVIEW

Read the release

Oslo, Norway (02 June 2020) - Reference is made to the stock exchange notice dated 29 May 2020 regarding the initial response to the offers by Kappa Bioscience to acquire shares in NattoPharma ASA ("NattoPharma") where the full Board of Directors in NattoPharma unanimously found that the Offer Price substantially undervalues the Company and its underlying values.

To further investigate value maximization alternatives for its shareholders, NattoPharma has engaged ABG Sundal Collier ASA to conduct a strategic review of the company. No assurance can be given regarding the outcome or timing of the process. NattoPharma will update shareholders and other stakeholders as and when relevant.

 

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements of section 5-12 of the Securities Trading Act.

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.